Navigation Links
Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
Date:12/5/2007

s decision. The decision is unrelated to the on-going NTI 0303 Phase III study, which is now close to completing recruitment and is expected to reach final data analysis and conclusions in 2008.

"XERECEPT(R) is an investigational new drug that may present a steroid- sparing alternative to dexamethasone. Dexamethasone is the only treatment currently available for PBE, but this corticosteroid is associated with debilitating side effects, including vision problems, muscle and bone loss, irritability, impaired wound healing and opportunistic infections."

NTI sold the worldwide rights and assets related to XERECEPT to Celtic Pharma in November 2005. NTI is entitled to receive milestone payments upon the achievement of certain regulatory objectives and, if XERECEPT, is approved for commercial sale, NTI is entitled to receive profit-sharing payments on sales in the United States and royalties on sales elsewhere in the world.

About Neurobiological Technologies, Inc.

NTI is specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late- stage clinical trials for central nervous system conditions. NTI is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For more information, please visit the company's website: http://www.ntii.com.

Forward-Looking Statements:

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including the limited control we have over the development and commercialization of XERECEPT, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those project
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... Move Policymakers to "Thoughtful Dialogue"WASHINGTON, Feb. 11 ... the merits of the Medicare Durable Medical Equipment, ... home oxygen leaders call on legislators to carefully ... on beneficiary services and much needed service-oriented jobs. ...
... COLUMBIA, S.C., Feb. 11 The Consortium for ... business, academic and economic development organizations intended to ... board and named Lonnie Emard as the interim ... information systems at BlueCross BlueShield of South Carolina, ...
... all-digital cancer hospital enhances commitment to quality care ... Feb. 11 Cancer Treatment Centers of America ... hospital in Goodyear, Ariz. The 213,000-square-foot facility is ... network. CTCA at Western Regional Medical Center ...
... St George,s, University of London measured recent exposure to tobacco ... Regional Heart Study by measuring the levels of cotinine - ... points 20 years apart. A blood cotinine level above 0.7ng/mL ... a heart attack (2), and other studies have suggested that ...
... 2009 "The House of Representatives and the Senate ... payment, on health care reform in the economic stimulus ... American College of Physicians, said today. ... that will provide adequate funding for critical health care ...
... Feb. 11 Z Trim Holdings,(OTC Bulletin Board: ZTHO), ... Valley,s E.D. Smith "Garden Goodness",French Style Dressing is made ... panel. , E.D. Smith, a ... being,the #1 store brand supplier of pourable dressings in ...
Cached Medicine News:Health News:As Congress Debates Competitive Bidding Program, Home Oxygen Beneficiaries and Providers Left to Cope with 27 Percent Cut to Medicare Home Oxygen Benefit 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 3Health News:Electronic Health Record Advances Patient-Centered Cancer Care 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 3Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 4
... The Vasculight VS system improves the ... (sun-induced freckles), most benign brown pigments, telangiectasias, ... of Intense Pulsed Light (IPLTM) treats pigmentary ... The unique, combined approach of IPL and ...
... The new IPL Quantum DL ... technology with the reliability and simplicity ... Its modular and upgradeable design protects ... the SR mode for IPL skin ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: